Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

140.35USD
21 Sep 2018
Change (% chg)

$-1.55 (-1.09%)
Prev Close
$141.90
Open
$141.45
Day's High
$142.40
Day's Low
$138.95
Volume
331,130
Avg. Vol
244,008
52-wk High
$236.05
52-wk Low
$119.90

Chart for

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $7,601.06
Shares Outstanding(Mil.): 54.16
Dividend: --
Yield (%): --

Financials

  BLUE.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -7.18 -- --
ROI: -23.22 1.50 12.72
ROE: -26.43 0.19 14.85

BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY

May 23 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

May 14 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31

* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

May 02 2018

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

Mar 28 2018

Earnings vs. Estimates